Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Net Cash Flow (2016 - 2025)

Traws Pharma (TRAW) has disclosed Net Cash Flow for 14 consecutive years, with -$4.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Cash Flow rose 64.51% to -$4.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.6 million, a 111.78% increase, with the full-year FY2024 number at $536000.0, up 102.99% from a year prior.
  • Net Cash Flow was -$4.1 million for Q3 2025 at Traws Pharma, down from -$2.9 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $29.0 million in Q1 2021 to a low of -$11.5 million in Q3 2024.
  • A 5-year average of -$1.1 million and a median of -$4.3 million in 2021 define the central range for Net Cash Flow.
  • Peak YoY movement for Net Cash Flow: skyrocketed 614.84% in 2021, then tumbled 156.79% in 2024.
  • Traws Pharma's Net Cash Flow stood at -$4.3 million in 2021, then increased by 9.67% to -$3.9 million in 2022, then fell by 14.06% to -$4.4 million in 2023, then surged by 459.75% to $15.9 million in 2024, then plummeted by 125.56% to -$4.1 million in 2025.
  • Per Business Quant, the three most recent readings for TRAW's Net Cash Flow are -$4.1 million (Q3 2025), -$2.9 million (Q2 2025), and -$5.4 million (Q1 2025).